A carregar...
Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Naïve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa
Objectives: In a multicenter, open-label, treatment protocol (HGT-REP-059; NCT01031173), clinical effects and tolerability of agalsidase alfa (agalα; 0.2 mg/kg every other week) were evaluated in patients with Fabry disease who were treatment naïve or switched from agalsidase beta (switch). Over 24...
Na minha lista:
| Publicado no: | JIMD Rep |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Berlin Heidelberg
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4484907/ https://ncbi.nlm.nih.gov/pubmed/25822820 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/8904_2015_422 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|